Conference Proceedings

Lorlatinib in patients with ALK plus NSCLC treated beyond initial disease progression

SI Ou, B Solomon, A Shaw, SM Gadgeel, B Besse, RA Soo, A Abbattista, H Thurm, F Toffalorio, RJ Wiltshire, A Bearz

Annals of Oncology | ELSEVIER | Published : 2020

Grants

Funding Acknowledgements

Pfizer Inc.